Failed drug discovery in psychiatry: Time for human genome-guided solutions

Trends in Cognitive Sciences

Volumn 19, Issue 4, 2015, Pages 183-187

  Papassotiropoulos, Andreas ^a,b,c   de Quervain, Dominique J F ^a,b  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSIS;

BIOLOGICAL MECHANISMS; COGNITIVE PROCESS; DISEASE MODELS; DRUG DISCOVERY; NEURAL MECHANISMS; PHARMACOLOGICAL TREATMENT; PSYCHIATRIC DISORDERS; THERAPEUTIC OUTCOMES;

DATA MINING;

DATA MINING; DRUG TARGETING; GENETIC ANALYSIS; HUMAN; HUMAN GENETICS; HUMAN GENOME; MENTAL DISEASE; PHENOTYPE; PSYCHIATRY; REVIEW; ANIMAL; BIOLOGICAL MODEL; DRUG DEVELOPMENT; GENETICS; MENTAL DISORDERS; PHARMACOGENETICS; PROCEDURES;

PSYCHOTROPIC AGENT;

ANIMALS; DATA MINING; DRUG DISCOVERY; GENOME, HUMAN; HUMANS; MENTAL DISORDERS; MODELS, BIOLOGICAL; PHARMACOGENETICS; PHENOTYPE; PSYCHOTROPIC DRUGS;

EID: 84925664429     PISSN: 13646613     EISSN: 1879307X     Source Type: Journal    
DOI: 10.1016/j.tics.2015.02.002     Document Type: Review

References (52)

1. Insel T.R. Next-generation treatments for mental disorders. Sci. Transl. Med. 2012, 4:155ps119.
2. Hyman S.E. Revolution stalled. Sci. Transl. Med. 2012, 4:155cm111.
3. Abbott A. Novartis to shut brain research facility. Nature 2011, 480:161-162.
4. Lander E.S. Initial impact of the sequencing of the human genome. Nature 2011, 470:187-197.
5. Collins F.S. Reengineering translational science: the time is right. Sci. Transl. Med. 2011, 3:90cm17.
6. Healy D.G., et al. Population genetics for target identification. Drug Discov. Today Technol. 2004, 1:69-74.
7. Muglia P. From genes to therapeutic targets for psychiatric disorders - what to expect?. Curr. Opin. Pharmacol. 2011, 11:563-571.
8. Rasetti R., Weinberger D.R. Intermediate phenotypes in psychiatric disorders. Curr. Opin. Genet. Dev. 2011, 21:340-348.
9. Plenge R.M., et al. Validating therapeutic targets through human genetics. Nat. Rev. Drug Discov. 2013, 12:581-594.
10. Schubert C.R., et al. Translating human genetics into novel treatment targets for schizophrenia. Neuron 2014, 84:537-541.
11. Sanseau P., et al. Use of genome-wide association studies for drug repositioning. Nat. Biotechnol. 2012, 30:317-320.
12. Papassotiropoulos A., et al. Human genome-guided identification of memory-modulating drugs. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:E4369-E4374.
13. Gustavsson A., et al. Cost of disorders of the brain in Europe 2010. Eur. Neuropsychopharmacol. 2011, 21:718-779.
14. Smith K. Trillion-dollar brain drain. Nature 2011, 478:15.
15. Editorial Of men, not mice. Nat. Med. 2013, 19:379.
16. Seok J., et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:3507-3512.
17. Editorial Best is yet to come. Nature 2011, 470:140.
18. Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014, 511:421-427. Schizophrenia Working Group of the Psychiatric Genomics Consortium.
19. Sklar P., et al. Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. Nat. Genet. 2011, 43:977-983.
20. Wang K., et al. Common genetic variants on 5p14.1 associate with autism spectrum disorders. Nature 2009, 459:528-533.
21. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet 2013, 381:1371-1379. Cross-Disorder Group of the Psychiatric Genomics Consortium and Genetic Risk and Outcome of Psychosis Consortium.
22. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) 2013, American Psychiatric Association, American Psychiatric Association.
23. McPartland J.C., et al. Sensitivity and specificity of proposed DSM-5 diagnostic criteria for autism spectrum disorder. J. Am. Acad. Child Adolesc. Psychiatry 2012, 51:368-383.
24. Kendler K.S., Gardner C.O. Boundaries of major depression: an evaluation of DSM-IV criteria. Am. J. Psychiatry 1998, 155:172-177.
25. Zammit S., et al. Psychotic experiences and psychotic disorders at age 18 in relation to psychotic experiences at age 12 in a longitudinal population-based cohort study. Am. J. Psychiatry 2013, 170:742-750.
26. Whittington J.E., Huppert F.A. Changes in the prevalence of psychiatric disorder in a community are related to changes in the mean level of psychiatric symptoms. Psychol. Med. 1996, 26:1253-1260.
27. van Os J. The dynamics of subthreshold psychopathology: implications for diagnosis and treatment. Am. J. Psychiatry 2013, 170:695-698.
28. Lundstrom S., et al. Autism spectrum disorders and autistic like traits: similar etiology in the extreme end and the normal variation. Arch. Gen. Psychiatry 2012, 69:46-52.
29. Anderson J., et al. Normality, deviance and minor psychiatric morbidity in the community. A population-based approach to General Health Questionnaire data in the Health and Lifestyle Survey. Psychol. Med. 1993, 23:475-485.
30. Toulopoulou T., et al. Substantial genetic overlap between neurocognition and schizophrenia: genetic modeling in twin samples. Arch. Gen. Psychiatry 2007, 64:1348-1355.
31. Quee P.J., et al. Cognitive subtypes in non-affected siblings of schizophrenia patients: characteristics and profile congruency with affected family members. Psychol. Med. 2014, 44:395-405.
32. David A.S. Why we need more debate on whether psychotic symptoms lie on a continuum with normality. Psychol. Med. 2010, 40:1935-1942.
33. Weinberger D.R., Goldberg T.E. RDoCs redux. World Psychiatry 2014, 13:36-38.
34. Gottesman I.I., Gould T.D. The endophenotype concept in psychiatry: etymology and strategic intentions. Am. J. Psychiatry 2003, 160:636-645.
35. Egan M.F., et al. Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:12604-12609.
36. Callicott J.H., et al. Variation in DISC1 affects hippocampal structure and function and increases risk for schizophrenia. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:8627-8632.
37. Esslinger C., et al. Neural mechanisms of a genome-wide supported psychosis variant. Science 2009, 324:605.
38. Bigos K.L., et al. Genetic variation in CACNA1C affects brain circuitries related to mental illness. Arch. Gen. Psychiatry 2010, 67:939-945.
39. Insel T., et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am. J. Psychiatry 2010, 167:748-751.
40. Manolio T.A. Genomewide association studies and assessment of the risk of disease. N. Engl. J. Med. 2010, 363:166-176.
41. Wang K., et al. Analysing biological pathways in genome-wide association studies. Nat. Rev. Genet. 2010, 11:843-854.
42. Mooney M.A., et al. Functional and genomic context in pathway analysis of GWAS data. Trends Genet. 2014, 30:390-400.
43. Heck A., et al. Converging genetic and functional brain imaging evidence links neuronal excitability to working memory, psychiatric disease, and brain activity. Neuron 2014, 81:1203-1213.
44. Voineagu I., et al. Transcriptomic analysis of autistic brain reveals convergent molecular pathology. Nature 2011, 474:380-384.
45. Holmans P., et al. Gene ontology analysis of GWA study data sets provides insights into the biology of bipolar disorder. Am. J. Hum. Genet. 2009, 85:13-24.
46. Stergiakouli E., et al. Investigating the contribution of common genetic variants to the risk and pathogenesis of ADHD. Am. J. Psychiatry 2012, 169:186-194.
47. O'Dushlaine C., et al. Molecular pathways involved in neuronal cell adhesion and membrane scaffolding contribute to schizophrenia and bipolar disorder susceptibility. Mol. Psychiatry 2011, 16:286-292.
48. Gaudet M.M., et al. Common genetic variants and modification of penetrance of BRCA2-associated breast cancer. PLoS Genet. 2010, 6:e1001183.
49. Okada Y., et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature 2014, 506:376-381.
50. Kathiresan S., et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat. Genet. 2008, 40:189-197.
51. Burkhardt R., et al. Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon13. Arterioscler. Thromb. Vasc. Biol. 2008, 28:2078-2084.
52. Altshuler D., et al. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat. Genet. 2000, 26:76-80.